Endo International PLC Company Profile (NASDAQ:ENDP)

About Endo International PLC (NASDAQ:ENDP)

Endo International PLC logoEndo International PLC, formerly Endo Health Solutions Inc. is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel. The Company operates in three segments: Endo Pharmaceuticals, Qualitest and AMS. In June 2014, the Company's subsidiary, Endo Pharmaceuticals sold its pharmaceutical drug discovery platform to AsanaBioSciences, LLC. In June 2014, Asana BioSciences, LLC, an independent member of Amneal Alliance of Companies, acquired early-stage branded pharmaceutical discovery platform of Endo Pharmaceuticals, a subsidiary of Endo International plc. In June 2014, Trendlines Group acquired intellectual property developed within the framework of an R&D agreement with the Company. In July 2014, it acquired Grupo Farmaceutico Somar.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Other
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:ENDP
  • CUSIP: 29264F20
  • Web: www.endo.com
Capitalization:
  • Market Cap: $2.76 billion
  • Outstanding Shares: 223,112,000
Average Prices:
  • 50 Day Moving Avg: $11.73
  • 200 Day Moving Avg: $12.05
  • 52 Week Range: $9.70 - $24.93
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 3.76
  • P/E Growth: -0.24
Sales & Book Value:
  • Annual Revenue: $4.08 billion
  • Price / Sales: 0.68
  • Book Value: $9.81 per share
  • Price / Book: 1.26
Profitability:
  • EBIDTA: $411.84 million
  • Net Margins: -82.93%
  • Return on Equity: 25.32%
  • Return on Assets: 6.90%
Debt:
  • Debt-to-Equity Ratio: 3.76%
  • Current Ratio: 1.13%
  • Quick Ratio: 0.87%
Misc:
  • Average Volume: 6.07 million shs.
  • Beta: 0.62
  • Short Ratio: 50.08
 
Frequently Asked Questions for Endo International PLC (NASDAQ:ENDP)

What is Endo International PLC's stock symbol?

Endo International PLC trades on the NASDAQ under the ticker symbol "ENDP."

How were Endo International PLC's earnings last quarter?

Endo International PLC (NASDAQ:ENDP) issued its earnings results on Tuesday, May, 9th. The company reported $1.23 earnings per share for the quarter, topping the Zacks' consensus estimate of $1.10 by $0.13. The business had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $1.02 billion. Endo International PLC had a negative net margin of 82.93% and a positive return on equity of 25.32%. The firm's revenue for the quarter was up 7.7% on a year-over-year basis. During the same period in the previous year, the company earned $1.08 earnings per share. View Endo International PLC's Earnings History.

What guidance has Endo International PLC issued on next quarter's earnings?

Endo International PLC issued an update on its FY17 earnings guidance on Tuesday, May, 9th. The company provided earnings per share (EPS) guidance of $3.45-3.75 for the period, compared to the Thomson Reuters consensus estimate of $3.61. The company issued revenue guidance of $3.45-3.60 billion, compared to the consensus revenue estimate of $3.54 billion.

Where is Endo International PLC's stock going? Where will Endo International PLC's stock price be in 2017?

19 equities research analysts have issued 1-year target prices for Endo International PLC's stock. Their predictions range from $12.00 to $27.00. On average, they expect Endo International PLC's share price to reach $16.94 in the next year. View Analyst Ratings for Endo International PLC.

What are analysts saying about Endo International PLC stock?

Here are some recent quotes from research analysts about Endo International PLC stock:

  • 1. According to Zacks Investment Research, "2017 will continue to be challenging for Endo as the generics base business and the legacy branded pain franchise are expected to decline further. Shares of Endo have significantly underperformed the Medical-Drugs industry in the past one year. The company’s Generic segment is also under pressure given the challenging competitive landscape and pricing pressures. With the  company pulling off Opana ER from the market over growing concern of opioid abuse epidemic, the top-line will be further impacted. Also, the Branded segment continues to be under pressure due to additional competitive entrants as well as a continuous rise in the number of public policy and regulatory actions. Concerns relating to pricing are expected to remain a major overhang on the shares. However, Endo’s top line should continue to benefit from robust performance of Xiaflex and sterile injectables." (7/11/2017)
  • 2. JMP Securities analysts commented, "The FDA panel voted 8 yes, 18 no, and 1 abstain on whether Opana ER's benefits outweigh the risk. The FDA was concerned that the new Opana ER formulation just shifts the abuse route from nasal to injections. We do not view Opana ER as a growth driver and it is only 4% of our 2017 revenue estimate while declining 13% y/y. Our $20 price target includes an equal blend of PEG ratio and EV/EBITDA analysis of 1.3x and 8.5x, respectively, on our 2017 estimates." (3/15/2017)
  • 3. Royal Bank Of Canada analysts commented, "Yesterday's AdComs' vote of 18 to 8 (one abstain) on OPANA ER's benefits no longer outweighing its risks will push a decision on the product's fate back to FDA. Whether it is removed or sees added restrictions we think it is likely we will see some downward P&L pressure but it is also worth noting that the stock was -25% in Mar ahead of the anticipated panel." (3/15/2017)
  • 4. Mizuho analysts commented, " We still like ENDP and its significant optionality, and we see upside to the stock for the following reasons: (1) Endo can likely sell Xiaflex for a healthy multiple with minimal EBITDA downside after cutting $30M in R&D expense for the planned cellulite trial and expenses tied to ~100 reps. (2) Endo may beat expectations following its conservative guide and/or longer than expected persistence of the Somar business, which is now also for sale. (3) Its high gross margin (55%) generic business with an attractive 117 ANDA pipeline, with 35 "first to files", is likely to attract consolidators in our view. (4) Its U.S.-based manufacturing plants contributed 95% of its production based on revenue, which may appeal to a potential buyer in the current political environment. We attribute remaining risk to a potential increase to the mesh liability accrual, but the company always has the option to litigate and delay. ENDP could therefore work in 2017 following an asset sale or takeover speculation. We reiterate our Buy rating and raise PT to $17 from $15 as we lower our WACC to 10% from 11% after mgmt. re-set expectations and the outlook." (3/3/2017)
  • 5. Guggenheim analysts commented, "ENDP reported a 4Q16 beat and guided down for '17, which was expected given pricing pressure in generics. Lack of earnings visibility in '18 remains a concern. That said, we think patience will be rewarded and execution against its stated objectives will drive multiple expansion for ENDP's stock toward our $35 PT. Also, ENDP continues to be open to strategic alternatives if it cannot enhance shareholder value on its own. We think ENDP could simplify its business by selling its brand assets to pay down debt. In our view, ENDP is also an interesting generics asset (#4 player) in a consolidating industry." (2/28/2017)

Are investors shorting Endo International PLC?

Endo International PLC saw a drop in short interest during the month of June. As of June 30th, there was short interest totalling 20,084,394 shares, a drop of 11.0% from the June 15th total of 22,575,855 shares. Based on an average trading volume of 5,194,844 shares, the days-to-cover ratio is currently 3.9 days. Currently, 10.1% of the company's stock are short sold.

Who are some of Endo International PLC's key competitors?

Who owns Endo International PLC stock?

Endo International PLC's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include First Quadrant L P CA (0.92%), American National Insurance Co. TX (0.06%), Oregon Public Employees Retirement Fund (0.03%), Meeder Asset Management Inc. (0.02%), Aperio Group LLC (0.02%) and Nisa Investment Advisors LLC (0.02%). Company insiders that own Endo International PLC stock include Arthur J Higgins, Matthew Joseph Maletta, Michael Hyatt, Nancy J Hutson, Paul Campanelli, Roger H Kimmel, Shane Cooke, Silva Rajiv De, Suketu Upadhyay, Susan Hall and William Spengler. View Institutional Ownership Trends for Endo International PLC.

Who sold Endo International PLC stock? Who is selling Endo International PLC stock?

Endo International PLC's stock was sold by a variety of institutional investors in the last quarter, including First Quadrant L P CA, Oregon Public Employees Retirement Fund and Aperio Group LLC. Company insiders that have sold Endo International PLC stock in the last year include Nancy J Hutson and Roger H Kimmel. View Insider Buying and Selling for Endo International PLC.

Who bought Endo International PLC stock? Who is buying Endo International PLC stock?

Endo International PLC's stock was acquired by a variety of institutional investors in the last quarter, including Nisa Investment Advisors LLC, James Investment Research Inc., Oakbrook Investments LLC, Capstone Asset Management Co. and Meeder Asset Management Inc.. Company insiders that have bought Endo International PLC stock in the last two years include Arthur J Higgins, Matthew Joseph Maletta, Paul Campanelli, Roger H Kimmel, Shane Cooke, Silva Rajiv De, Suketu Upadhyay, Susan Hall and William Spengler. View Insider Buying and Selling for Endo International PLC.

How do I buy Endo International PLC stock?

Shares of Endo International PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Endo International PLC's stock price today?

One share of Endo International PLC stock can currently be purchased for approximately $12.38.


MarketBeat Community Rating for Endo International PLC (NASDAQ ENDP)
Community Ranking:  2.6 out of 5 ( )
Outperform Votes:  562 (Vote Outperform)
Underperform Votes:  518 (Vote Underperform)
Total Votes:  1,080
MarketBeat's community ratings are surveys of what our community members think about Endo International PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Endo International PLC (NASDAQ:ENDP) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 14 Hold Ratings, 5 Buy Ratings
Consensus Rating:Hold (Score: 2.26)
Consensus Price Target: $16.94 (36.84% upside)

Analysts' Ratings History for Endo International PLC (NASDAQ:ENDP)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/16/2017Royal Bank Of CanadaSet Price TargetHold$15.00MediumView Rating Details
7/7/2017Deutsche Bank AGLower Price TargetBuy$18.00 -> $15.00MediumView Rating Details
6/17/2017GuggenheimInitiated CoverageHold$12.00MediumView Rating Details
6/16/2017Cantor FitzgeraldInitiated CoverageNeutral -> Neutral$12.00LowView Rating Details
6/14/2017William BlairReiterated RatingMarket PerformLowView Rating Details
6/9/2017Stifel NicolausDowngradeBuy -> Hold$22.00 -> $15.00HighView Rating Details
6/8/2017Oppenheimer Holdings, Inc.Reiterated RatingHoldHighView Rating Details
6/8/2017Canaccord GenuitySet Price TargetHold$14.00 -> $12.00HighView Rating Details
5/25/2017MizuhoReiterated RatingBuy -> Buy$18.00 -> $19.00LowView Rating Details
5/17/2017BMO Capital MarketsReiterated RatingHold$16.00HighView Rating Details
3/20/2017Leerink SwannReiterated RatingMarket PerformLowView Rating Details
3/15/2017JMP SecuritiesReiterated RatingOutperform$20.00HighView Rating Details
2/6/2017Barclays PLCLower Price TargetEqual Weight$22.00 -> $15.00N/AView Rating Details
1/31/2017Susquehanna Bancshares IncUpgradeNeutral -> PositiveN/AView Rating Details
1/27/2017Piper Jaffray CompaniesSet Price TargetHold$12.00N/AView Rating Details
1/20/2017J P Morgan Chase & CoDowngradeOverweight -> Neutral$20.00N/AView Rating Details
1/5/2017Citigroup Inc.DowngradeBuy -> Neutral$25.00 -> $20.00N/AView Rating Details
9/29/2016Northland SecuritiesUpgradeMarket Perform -> Outperform$27.00N/AView Rating Details
9/8/2016Morgan StanleySet Price TargetHold$15.00 -> $16.00N/AView Rating Details
6/6/2016Goldman Sachs Group, Inc. (The)Initiated CoverageNeutral$20.00N/AView Rating Details
4/2/2016NomuraReiterated RatingBuyN/AView Rating Details
11/13/2015Standpoint ResearchUpgradeHold -> Buy$75.00N/AView Rating Details
(Data available from 7/24/2015 forward)

Earnings

Earnings History for Endo International PLC (NASDAQ:ENDP)
Earnings by Quarter for Endo International PLC (NASDAQ:ENDP)
Earnings History by Quarter for Endo International PLC (NASDAQ ENDP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2017Q1 17$1.10$1.23$1.02 billion$1.04 billionViewListenView Earnings Details
2/28/2017Q416$1.63$1.77$1.17 billion$1.24 billionViewListenView Earnings Details
11/8/2016Q316$0.81$1.01$862.47 million$894.30 millionViewListenView Earnings Details
8/8/2016Q216$0.74$0.86$873.50 million$921.00 millionViewListenView Earnings Details
5/5/2016Q116$1.04$1.08$960.96 million$963.54 millionViewListenView Earnings Details
2/29/2016Q415$1.27$1.36$1.07 billion$1.07 billionViewListenView Earnings Details
11/5/2015Q315$1.00$1.02$736.16 million$746.00 millionViewListenView Earnings Details
8/10/2015Q215$1.02$1.08$727.45 million$735.00 millionViewListenView Earnings Details
5/11/2015Q115$1.07$1.17$714.42 million$714.00 millionViewListenView Earnings Details
3/2/2015Q414$1.13$1.16$780.44 million$800.00 millionViewListenView Earnings Details
11/5/2014Q314$0.99$1.15$721.11 million$764.00 millionViewListenView Earnings Details
7/31/2014Q214$0.90$1.06$644.60 million$719.00 millionViewListenView Earnings Details
5/1/2014Q114$0.84$0.92$608.86 million$595.00 millionViewListenView Earnings Details
2/28/2014Q413$0.93$0.96$620.90 million$584.95 millionViewListenView Earnings Details
11/7/2013Q313$1.11$1.34$695.63 million$715.00 millionViewListenView Earnings Details
8/6/2013Q2 2013$1.15$1.42$721.01 million$766.51 millionViewListenView Earnings Details
5/7/2013Q1 2013$1.08$1.09$737.79 million$709.00 millionViewListenView Earnings Details
2/28/2013Q4 2012$1.54$1.62$807.98 million$801.06 millionViewListenView Earnings Details
11/5/2012Q312$1.26$1.28$788.53 million$750.50 millionViewN/AView Earnings Details
8/7/2012$1.19$1.27ViewN/AView Earnings Details
5/1/2012$0.86$0.87ViewN/AView Earnings Details
2/24/2012$1.32$1.40ViewN/AView Earnings Details
10/27/2011$1.28$1.25ViewN/AView Earnings Details
8/9/2011$1.06$1.05ViewN/AView Earnings Details
4/28/2011$1.00$1.00ViewN/AView Earnings Details
2/28/2011$0.97$1.06ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Endo International PLC (NASDAQ:ENDP)
2017 EPS Consensus Estimate: $3.38
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$1.08$1.26$1.15
Q2 20173$0.75$0.80$0.77
Q3 20173$0.68$0.74$0.72
Q4 20173$0.66$0.84$0.74
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Endo International PLC (NASDAQ:ENDP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Endo International PLC (NASDAQ:ENDP)
Insider Ownership Percentage: 0.50%
Institutional Ownership Percentage: 93.17%
Insider Trades by Quarter for Endo International PLC (NASDAQ:ENDP)
Institutional Ownership by Quarter for Endo International PLC (NASDAQ:ENDP)
Insider Trades by Quarter for Endo International PLC (NASDAQ:ENDP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/16/2017Paul CampanelliCEOBuy2,300$10.72$24,656.00View SEC Filing  
3/9/2017Nancy J. HutsonDirectorSell5,325$10.82$57,616.50View SEC Filing  
11/15/2016Roger H. KimmelDirectorSell14,000$17.38$243,320.00View SEC Filing  
5/11/2016Arthur J HigginsDirectorBuy5,000$13.80$69,000.00View SEC Filing  
5/10/2016Arthur J HigginsDirectorBuy11,000$15.42$169,620.00View SEC Filing  
5/10/2016Paul CampanelliInsiderBuy13,000$15.53$201,890.00View SEC Filing  
3/17/2016William SpenglerDirectorBuy1,000$29.20$29,200.00View SEC Filing  
3/16/2016William SpenglerDirectorBuy1,000$35.24$35,240.00View SEC Filing  
3/14/2016Roger H KimmelDirectorBuy1,125$41.94$47,182.50View SEC Filing  
3/7/2016Matthew Joseph MalettaVPBuy500$44.48$22,240.00View SEC Filing  
3/7/2016Silva Rajiv DeCEOBuy2,250$44.50$100,125.00View SEC Filing  
3/1/2016Nancy J. HutsonDirectorSell3,413$42.19$143,994.47View SEC Filing  
11/12/2015Shane CookeDirectorBuy4,000$57.13$228,520.00View SEC Filing  
11/11/2015Michael HyattDirectorSell8,000$55.48$443,840.00View SEC Filing  
11/11/2015Paul CampanelliinsiderBuy2,100$55.69$116,949.00View SEC Filing  
11/11/2015Silva Rajiv DeCEOBuy9,006$55.52$500,013.12View SEC Filing  
11/11/2015Suketu UpadhyayCFOBuy4,450$56.37$250,846.50View SEC Filing  
11/11/2015Susan HallEVPBuy1,000$55.35$55,350.00View SEC Filing  
6/16/2015Arthur J HigginsDirectorBuy2,500$81.10$202,750.00View SEC Filing  
4/8/2015Caroline B ManogueVPSell105,562$91.90$9,701,147.80View SEC Filing  
11/14/2014Suketu UpadhyayCFOBuy3,700$66.94$247,678.00View SEC Filing  
8/5/2014Arthur J HigginsDirectorBuy3,500$65.65$229,775.00View SEC Filing  
6/9/2014John DeluccaDirectorSell6,764$68.83$465,566.12View SEC Filing  
5/29/2014Caroline B ManogueVPSell175,033$72.02$12,605,876.66View SEC Filing  
5/1/2014John DeluccaDirectorSell8,094$66.31$536,713.14View SEC Filing  
4/1/2014John DeluccaDirectorSell10,384$68.46$710,888.64View SEC Filing  
3/10/2014Arthur HigginsDirectorBuy5,000$73.00$365,000.00View SEC Filing  
3/10/2014Ivan GergelEVPSell75,637$72.47$5,481,413.39View SEC Filing  
8/26/2013Caroline ManogueVPSell145,592$39.40$5,736,324.80View SEC Filing  
8/8/2013Roger KimmelDirectorBuy5,478$36.50$199,947.00View SEC Filing  
4/9/2013Caroline B ManogueVPSell35,000$35.00$1,225,000.00View SEC Filing  
11/12/2012David HolveckCEOBuy7,425$26.84$199,287.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Endo International PLC (NASDAQ:ENDP)
Latest Headlines for Endo International PLC (NASDAQ:ENDP)
Source:
DateHeadline
marketwatch.com logoEndo to cut 875 jobs and close facilities in Alabama - MarketWatch - MarketWatch
www.marketwatch.com - July 22 at 11:33 PM
finance.yahoo.com logoEndo to Restructure Manufacturing Network
finance.yahoo.com - July 22 at 1:10 AM
finance.yahoo.com logoEndo Says Shipments of Opana ER Will End Sept. 1
finance.yahoo.com - July 22 at 1:10 AM
prnewswire.com logoEndo to Restructure Manufacturing Network - PR Newswire (press release)
www.prnewswire.com - July 21 at 8:09 PM
americanbankingnews.com logoEndo International PLC (ENDP) Expected to Post Quarterly Sales of $842.14 Million
www.americanbankingnews.com - July 20 at 9:59 AM
finance.yahoo.com logoNektar's NKTR-181 Positive in Human Abuse Potential Study
finance.yahoo.com - July 19 at 9:46 PM
americanbankingnews.com logoWilliam Blair Comments on Endo International PLC's Q3 2017 Earnings (ENDP)
www.americanbankingnews.com - July 19 at 10:54 AM
americanbankingnews.com logo Analysts Anticipate Endo International PLC (ENDP) Will Announce Earnings of $0.73 Per Share
www.americanbankingnews.com - July 19 at 12:16 AM
finance.yahoo.com logoEndo International Plc breached its 50 day moving average in a Bullish Manner : ENDP-US : July 18, 2017
finance.yahoo.com - July 18 at 7:48 PM
finance.yahoo.com logo[$$] Pharma Firms Fighting Opioid Abuse
finance.yahoo.com - July 18 at 7:48 PM
finance.yahoo.com logoHow This Biotech Could Dethrone Oxycodone In Treating Pain
finance.yahoo.com - July 18 at 7:48 PM
americanbankingnews.com logoHead-To-Head Analysis: Biodel (ALBO) versus Endo International PLC (NASDAQ:ENDP)
www.americanbankingnews.com - July 18 at 1:17 PM
americanbankingnews.com logoEndo International PLC (ENDP) Given a $15.00 Price Target by Royal Bank Of Canada Analysts
www.americanbankingnews.com - July 18 at 12:56 AM
americanbankingnews.com logoAnalysts Set Expectations for Endo International PLC's Q2 2017 Earnings (NASDAQ:ENDP)
www.americanbankingnews.com - July 17 at 7:47 AM
americanbankingnews.com logoAnalyzing Biodel (ALBO) and Endo International PLC (ENDP)
www.americanbankingnews.com - July 16 at 8:12 PM
americanbankingnews.com logoShort Interest in Endo International PLC (ENDP) Declines By 11.0%
www.americanbankingnews.com - July 15 at 7:06 AM
finance.yahoo.com logoEndo to Announce Second-Quarter 2017 Financial Results
finance.yahoo.com - July 14 at 9:02 PM
americanbankingnews.com logoEndo International PLC (NASDAQ:ENDP) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - July 14 at 5:05 PM
americanbankingnews.com logoQ3 2017 EPS Estimates for Endo International PLC Decreased by Analyst (ENDP)
www.americanbankingnews.com - July 14 at 12:02 PM
nasdaq.com logoBioDelivery-Purdue Pharma Ink Marketing Deal for Pain Drug - Nasdaq
www.nasdaq.com - July 13 at 7:36 PM
businesswire.com logoENDP SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Endo ...
www.businesswire.com - July 13 at 4:59 AM
finance.yahoo.com logoENDP SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Endo International plc
finance.yahoo.com - July 12 at 6:57 PM
finance.yahoo.com logoRepublican Push To Oust ObamaCare Nears Deadline
finance.yahoo.com - July 12 at 1:07 AM
americanbankingnews.com logoZacks Investment Research Downgrades Endo International PLC (ENDP) to Sell
www.americanbankingnews.com - July 11 at 7:14 PM
finance.yahoo.com logoFDA Chief Says Agency Must Do More to Stop Abuse of Opioids
finance.yahoo.com - July 10 at 6:09 PM
americanbankingnews.com logoResearch Analysts Issue Forecasts for Endo International PLC's FY2020 Earnings (ENDP)
www.americanbankingnews.com - July 10 at 10:13 AM
americanbankingnews.com logoHead to Head Comparison: Alexza Pharmaceuticals (ALXA) versus Endo International PLC (NASDAQ:ENDP)
www.americanbankingnews.com - July 9 at 8:23 AM
News IconA painkiller at the heart of the opioid epidemic has been taken off the market - Business Insider
www.businessinsider.com - July 8 at 10:53 PM
nasdaq.com logoEndo (ENDP) to Remove Opioid Pain Drug Opana ER from Market - Nasdaq
www.nasdaq.com - July 8 at 5:50 PM
streetinsider.com logoEndo International plc (ENDP) PT Lowered to $15 at Deutsche Bank Following Opana ER Withdrawal - StreetInsider.com
www.streetinsider.com - July 8 at 5:50 PM
americanbankingnews.com logoAnalyzing Endo International PLC (NASDAQ:ENDP) and Alexza Pharmaceuticals (ALXA)
www.americanbankingnews.com - July 8 at 10:40 AM
finance.yahoo.com logoEndo's Potential Next Steps After Pulling Opioid Pain Med
finance.yahoo.com - July 8 at 10:31 AM
finance.yahoo.com logoSHAREHOLDER ALERT: Lundin Law PC Announces an Investigation of Endo International plc and Advises Investors with Losses to Contact the Firm
finance.yahoo.com - July 8 at 10:31 AM
americanbankingnews.com logoFY2017 Earnings Estimate for Endo International PLC Issued By Gabelli (ENDP)
www.americanbankingnews.com - July 7 at 11:50 AM
americanbankingnews.com logoEndo International PLC (ENDP) PT Lowered to $15.00
www.americanbankingnews.com - July 7 at 10:18 AM
finance.yahoo.com logoWhy Flexion Therapeutics Rallied 18% in June
finance.yahoo.com - July 7 at 12:32 AM
businesswire.com logoENDP INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Endo ...
www.businesswire.com - July 6 at 7:31 PM
finance.yahoo.com logoEndo Provides Update On OPANA® ER
finance.yahoo.com - July 6 at 7:31 PM
finance.yahoo.com logoA painkiller at the heart of the opioid epidemic has been taken off the market
finance.yahoo.com - July 6 at 7:31 PM
finance.yahoo.com logoOpioid Prescriptions Ebb but Addiction, Overdoses Still Vex U.S.
finance.yahoo.com - July 6 at 7:31 PM
finance.yahoo.com logoEndo will remove opioid from market, following FDA request
finance.yahoo.com - July 6 at 7:31 PM
finance.yahoo.com logoEndo agrees to pull opioid medicine from the market
finance.yahoo.com - July 6 at 7:31 PM
finance.yahoo.com logo[$$] Endo to Pull Painkiller Opana From U.S. Market
finance.yahoo.com - July 6 at 7:31 PM
finance.yahoo.com logoENDP INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Endo International plc
finance.yahoo.com - July 6 at 7:31 PM
finance.yahoo.com logoEndo pulls opioid as U.S. seeks to tackle abuse epidemic
finance.yahoo.com - July 6 at 7:31 PM
marketbeat.com logoPainkiller maker stops sales at FDA request because of abuse
marketbeat.com - July 6 at 4:55 PM
finance.yahoo.com logoEndo Announces Divestiture of Grupo Farmacéutico SOMAR
finance.yahoo.com - July 5 at 6:57 PM
finance.yahoo.com logo[$$] Endo Selling Mexican Operation to Advent
finance.yahoo.com - July 5 at 6:57 PM
finance.yahoo.com logoHow Have The Best And Worst Stocks Of 2016 Performed In 2017?
finance.yahoo.com - July 5 at 6:57 PM
finance.yahoo.com logoEndo Completes Divestiture of Litha Healthcare Group
finance.yahoo.com - July 3 at 6:06 PM

Social

Chart

Endo International PLC (ENDP) Chart for Monday, July, 24, 2017

This page was last updated on 7/24/2017 by MarketBeat.com Staff